Press release
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) announces that Dave Gardner has been appointed Executive Vice President and Chief Strategy Officer (CSO) effective today, September 22, 2025. In his new role, Mr. Gardner will serve as a key member of the Executive Leadership Team and be responsible for the Company’s strategy and business development.\n\n\n\"Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development,\" said Bill Meury, President and Chief Executive Officer, Incyte. \"Dave will play a pivotal role in developing a coherent and executable long-term growth strategy for the company and ensuring our portfolio decisions, business development and strategic partnerships position Incyte for sustainable value creation.\"\n\n\nWith more than 20 years of experience in pharmaceutical and biotechnology investing and advising, Mr. Gardner most recently served as Partner on the Therapeutics Team at Rock Springs Capital Management, leading strategy across Oncology, Neurology, Immunology and Rare Diseases. Prior to that, Mr. Gardner spent a decade at BlackRock as Vice President and Equity Research Analyst where he was responsible for the Health Care sector. He holds an Executive MBA from Columbia Business School and a bachelor’s degree from the University of Virginia’s McIntire School of Commerce.\n\n\nAfter nine years as a key member of the Incyte leadership team, Vijay Iyengar, M.D., Executive Vice President and Head of Global Medical Affairs and Product and Partnership Strategy, will be retiring from Incyte and continue to provide transitional support to Mr. Gardner through the end of the year.\n\n\nAbout Incyte\n\n\nA global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.\n\n\nFor additional information on Incyte, plea...